Badenoch James, Cavanna Andrea E
Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK.
School of Life and Health Sciences, Aston University, Birmingham, UK.
Neurol Sci. 2020 Jul;41(7):1923-1926. doi: 10.1007/s10072-020-04327-3. Epub 2020 Mar 13.
Tourette syndrome (TS) and persistent motor/vocal tic disorders are neurodevelopmental conditions characterised by the chronic presence of motor and/or vocal tics. Patients with TS often present with co-morbid disorders, especially attention-deficit and hyperactivity disorder (which tends to improve after childhood), and obsessive-compulsive disorder (which can persist in adulthood). We set out to explore pharmacotherapy for tics in adult patients with TS and persistent motor/vocal tic disorders, as well as its relationship with the presence of co-morbid conditions.
We retrospectively reviewed the clinical characteristics and pharmacotherapy of 192 adult patients with TS (n = 187), persistent motor tic disorder (n = 3) and persistent vocal tic disorder (n = 2) attending a specialist clinic in the UK.
Anti-dopaminergic medications (n = 65) and alpha-2-agonists (n = 50) were the most commonly prescribed pharmacotherapy for tic management. A sub-group analysis revealed that co-morbid obsessive-compulsive disorder and sub-threshold obsessive-compulsive behaviours were significantly more common in patients treated with anti-dopaminergic medications than patients taking alpha-2-agonists (p = 0.013 and p = 0.047, respectively).
The use of pharmacotherapy options for tic management observed at a specialist clinic for adults with TS reflects guideline recommendations. We found that the presence of co-morbid obsessive-compulsive disorder/behaviours correlates with the choice of anti-dopaminergic medications over alpha-2-agonists, in line with available evidence on the efficacy of anti-dopaminergic medications for the treatment of specific tic-related behavioural symptoms.
抽动秽语综合征(TS)以及持续性运动性/发声性抽动障碍是神经发育性疾病,其特征为慢性存在运动性和/或发声性抽动。TS患者常伴有共病,尤其是注意缺陷多动障碍(往往在儿童期后有所改善)和强迫症(可在成年期持续存在)。我们着手探讨成年TS患者及持续性运动性/发声性抽动障碍患者抽动症状的药物治疗方法及其与共病情况的关系。
我们回顾性分析了在英国一家专科诊所就诊的192例成年患者的临床特征和药物治疗情况,其中TS患者187例,持续性运动性抽动障碍患者3例,持续性发声性抽动障碍患者2例。
抗多巴胺能药物(65例)和α-2激动剂(50例)是治疗抽动症状最常用的药物。亚组分析显示,与服用α-2激动剂的患者相比,接受抗多巴胺能药物治疗的患者共病强迫症及阈下强迫行为明显更为常见(分别为p = 0.013和p = 0.047)。
在针对成年TS患者的专科诊所观察到的抽动症状药物治疗选择符合指南推荐。我们发现,共病强迫症/强迫行为与选择抗多巴胺能药物而非α-2激动剂相关,这与抗多巴胺能药物治疗特定抽动相关行为症状疗效的现有证据一致。